Grandfield & Dodd LLC Grows Holdings in Exact Sciences Corporation $EXAS

Grandfield & Dodd LLC increased its holdings in shares of Exact Sciences Corporation (NASDAQ:EXAS) by 3.4% in the second quarter, Holdings Channel reports. The firm owned 116,547 shares of the medical research company’s stock after buying an additional 3,787 shares during the quarter. Grandfield & Dodd LLC’s holdings in Exact Sciences were worth $6,193,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently bought and sold shares of the company. Great Lakes Advisors LLC boosted its stake in shares of Exact Sciences by 3.7% during the first quarter. Great Lakes Advisors LLC now owns 4,971 shares of the medical research company’s stock worth $215,000 after buying an additional 178 shares during the period. Nissay Asset Management Corp Japan ADV lifted its position in Exact Sciences by 0.8% during the 1st quarter. Nissay Asset Management Corp Japan ADV now owns 22,432 shares of the medical research company’s stock worth $971,000 after acquiring an additional 187 shares during the period. DekaBank Deutsche Girozentrale grew its stake in shares of Exact Sciences by 0.4% in the 2nd quarter. DekaBank Deutsche Girozentrale now owns 58,333 shares of the medical research company’s stock valued at $3,127,000 after purchasing an additional 217 shares during the last quarter. IFP Advisors Inc increased its holdings in shares of Exact Sciences by 6.5% in the second quarter. IFP Advisors Inc now owns 4,466 shares of the medical research company’s stock valued at $237,000 after purchasing an additional 273 shares during the period. Finally, Farther Finance Advisors LLC raised its stake in shares of Exact Sciences by 37.0% during the second quarter. Farther Finance Advisors LLC now owns 1,018 shares of the medical research company’s stock worth $54,000 after purchasing an additional 275 shares during the last quarter. 88.82% of the stock is currently owned by institutional investors and hedge funds.

Exact Sciences Stock Down 0.9%

Shares of NASDAQ EXAS opened at $67.75 on Friday. The firm has a market cap of $12.84 billion, a P/E ratio of -12.48, a price-to-earnings-growth ratio of 5.56 and a beta of 1.34. The company has a debt-to-equity ratio of 0.94, a quick ratio of 2.56 and a current ratio of 2.89. Exact Sciences Corporation has a 1 year low of $38.81 and a 1 year high of $72.81. The firm’s 50 day moving average price is $59.57 and its 200 day moving average price is $54.03.

Exact Sciences (NASDAQ:EXAS) last announced its quarterly earnings data on Monday, November 3rd. The medical research company reported $0.24 EPS for the quarter, beating analysts’ consensus estimates of $0.13 by $0.11. The business had revenue of $850.74 million during the quarter, compared to the consensus estimate of $810.42 million. Exact Sciences had a negative return on equity of 1.75% and a negative net margin of 34.19%.The business’s revenue for the quarter was up 20.0% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.21) earnings per share. Exact Sciences has set its FY 2025 guidance at EPS. As a group, sell-side analysts anticipate that Exact Sciences Corporation will post -0.58 earnings per share for the current year.

Insiders Place Their Bets

In other Exact Sciences news, Director James Edward Doyle sold 2,000 shares of the stock in a transaction that occurred on Thursday, October 9th. The shares were sold at an average price of $60.00, for a total value of $120,000.00. Following the completion of the sale, the director owned 57,962 shares of the company’s stock, valued at $3,477,720. This trade represents a 3.34% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Brian Baranick sold 2,858 shares of the firm’s stock in a transaction on Tuesday, November 4th. The shares were sold at an average price of $70.08, for a total transaction of $200,288.64. Following the sale, the executive vice president directly owned 22,368 shares of the company’s stock, valued at approximately $1,567,549.44. The trade was a 11.33% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Company insiders own 1.20% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on EXAS shares. UBS Group lowered their target price on shares of Exact Sciences from $61.00 to $53.00 and set a “neutral” rating on the stock in a report on Thursday, August 7th. Stifel Nicolaus raised their price target on Exact Sciences from $67.00 to $80.00 and gave the company a “buy” rating in a research report on Tuesday, November 4th. Robert W. Baird boosted their price objective on shares of Exact Sciences from $72.00 to $88.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 4th. Wall Street Zen cut shares of Exact Sciences from a “buy” rating to a “hold” rating in a research report on Saturday, November 8th. Finally, Barclays upped their price target on shares of Exact Sciences from $65.00 to $77.00 and gave the company an “overweight” rating in a report on Tuesday, November 4th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Exact Sciences presently has a consensus rating of “Moderate Buy” and an average target price of $74.06.

Exact Sciences Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.